No quantitative synthesis was attempted for either mebiomian plugging or meibomian secretion scores and no significant changes were observed with any other outcome parameter .
Conclusion : Only the systemic antimicrobials were found to improve the clinical features of meibomian gl and dysfunction .
Varying effects of different therapeutic agents ( heat therapies , omega-3-fatty acids and castor oil ) were identified for MGD but the risk of bias pertaining to r and omization and allocation concealment was found to be associated with most of the current RCTs .
Introduction : Meibomian Gl and Dysfunction ( MGD ) is a common , often overlooked , chronic condition affecting eyes for which various therapies are being evaluated .
Considering the absence of a systematic review and meta- analysis , the present review was carried out .
Efficacy of Commercially Available Topical Cyclosporine A 0.05% in the Treatment of Meibomian Gland Dysfunction
Objective : To investigate the efficacy of topical cyclosporine A 0.05 % ( tCsA ) ( Restasis ® , Allergan Pharmaceuticals ) in the treatment of meibomian gl and dysfunction ( posterior blepharitis ) . Methods : Thirty-three patients with symptomatic meibomian gl and dysfunction were r and omized in a prospect i ve study to either tCsA or placebo ( Refresh Plus ® preservative-free artificial tears ) , 2 times daily for 3 months . They were evaluated at baseline and at 1 , 2 , and 3 months for subjective symptoms and objective signs including meibomian gl and inclusion s , lid margin vascular injection , tarsal telangiectasis , fluorescein staining , tear breakup time , and Schirmer scores . Results : Twenty-six patients completed the study . All patients were tested for ocular symptoms , lid margin vascularity , tarsal telangiectasis , meibomian gl and inclusion s , tear breakup time , and fluorescein staining . At the 3-month visit , the tCsA group showed a greater improvement in ocular symptoms than the placebo group , but this difference was not statistically significant . At the 3-month visit , several objective examination findings were statistically significantly ( P < 0.05 ) improved in the tCsA group compared with the placebo group . These differences included lid margin vascular injection , tarsal telangiectasis , and fluorescein staining . The most significant finding ( P = 0.001 ) was the greater decrease in the number of meibomian gl and inclusion s in the tCsA group compared with the placebo group . Conclusions : Topical CsA may be helpful in the treatment of meibomian gl and dysfunction ( posterior blepharitis ) . Topical CsA did not induce an improvement in the symptoms , but it did decrease the number of meibomian gl and inclusion s in patients with meibomian gl and dysfunction
No quantitative synthesis was attempted for either mebiomian plugging or meibomian secretion scores and no significant changes were observed with any other outcome parameter .
Conclusion : Only the systemic antimicrobials were found to improve the clinical features of meibomian gl and dysfunction .
Varying effects of different therapeutic agents ( heat therapies , omega-3-fatty acids and castor oil ) were identified for MGD but the risk of bias pertaining to r and omization and allocation concealment was found to be associated with most of the current RCTs .
Introduction : Meibomian Gl and Dysfunction ( MGD ) is a common , often overlooked , chronic condition affecting eyes for which various therapies are being evaluated .
Considering the absence of a systematic review and meta- analysis , the present review was carried out .